private financing

The company said it will use proceeds from the round, which was led by Casdin Capital, to expand and commercialize its SomaScan platform and SomaSignal tests.

Under the terms of the agreement, OpGen would sell $10 million in stock and warrants to a US-based healthcare-focused institutional investor.

The company said the funds would be used in part to expand its presence in the cell-analysis market in areas such as infectious disease.

The company is developing technology to analyze capillary blood samples from a finger prick using one-tenth the volume typically collected by traditional venipuncture.

The Wilmington, Delaware-based startup will use the funds for clinical validation trials on its Arna Breast cancer diagnostic test in the US and Europe. 

The Belgian home testing company said it will use the money to initiate clinical development for a urine-based self-test for chlamydia and gonorrhea.

The financing round was led by Asian private investment firm AT Capital and early-stage deep-tech venture capital fund Elev8.vc.

The financing will be used for the development and clinical validation of oncology panels for treatment selection and patient monitoring with an initial focus on NSCLC.